Physician_Profile_ID,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_Name,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_State,Applicable_Manufacturer_or_Applicable_GPO_Making_Payment_ID,Total_Amount_of_Payment_USDollars,Date_of_Payment,Form_of_Payment_or_Transfer_of_Value,Record_ID,Name_of_Associated_Covered_Drug_or_Biological1,Name_of_Associated_Covered_Drug_or_Biological2,Name_of_Study,Research_Information_Link,Context_of_Research
256009,"Merck Sharp & Dohme Corporation",NJ,100000000053,429.10,11/11/2013,"In-kind items and services",24490852,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
256009,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,295.00,04/24/2015,"Cash or cash equivalent",294351806,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
256009,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,295.00,08/13/2015,"Cash or cash equivalent",294351810,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
256009,"Valeant Pharmaceuticals North America LLC",NJ,100000010935,295.00,12/10/2015,"Cash or cash equivalent",294351814,PROVENGE,"","A REGISTRY OF SIPULEUCEL-T THERAPY IN MEN WITH ADVANCED PROSTATE CANCER","",""
256009,"Merck Sharp & Dohme Corporation",NJ,100000000053,85.82,10/11/2013,"In-kind items and services",24490884,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
256009,"Merck Sharp & Dohme Corporation",NJ,100000000053,81.48,10/11/2013,"In-kind items and services",24490853,"EMEND for Injection","","A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Parallel-Group Study, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of a Single 150 mg Dose of In","",""
